However, men with higher PSA levels did show modest improvements in survival, suggesting that hormone therapy might be worthwhile for them. PSA (prostate-specific antigen) is produced by the prostate ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

No significant improvement seen in overall survival with addition of hormone therapy to post-radical prostatectomy radiotherapy.

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...